Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2025-03-10 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物自愿披露关于D-2570治疗银屑病II期临床研究结果在2025年美国皮肤病学会（AAD）年会发布的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by the company Yifang Bio (益方生物科技) regarding the results of a Phase II clinical trial for their drug D-2570, presented at the 2025 American Academy of Dermatology (AAD) annual meeting. It contains detailed clinical trial efficacy and safety data, but it is framed as a public announcement of clinical trial results rather than a full financial or regulatory report. The document is relatively short (1560 characters) and structured as a formal announcement to investors about clinical progress and risk warnings. It does not contain financial statements, management discussion, or regulatory certifications. It is not an earnings release or annual/interim report. It is not a regulatory filing or certification. It is a clinical trial result announcement, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-03-10 Chinese
益方生物关于持股5%以上股东及其一致行动人权益变动触及1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding changes in shareholding percentages by shareholders holding more than 5% of the company's shares and their concerted actors. It details the shareholding changes, including dates, quantities, and percentages, and confirms that these changes do not affect the controlling shareholder or actual controller. The document is titled as a "提示性公告" (prompting announcement) about equity changes touching 1%. It does not contain financial statements or detailed financial analysis but is a regulatory disclosure about major shareholding changes. The document length is 3843 characters, which is relatively short and consistent with a notification rather than a full report. Therefore, it fits the category of Major Shareholding Notification (MRQ).
2025-02-28 Chinese
益方生物2024年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024 年度业绩快报公告" which translates to "2024 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2024, including revenue, net profit, and other financial metrics. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited data will be in the 2024 Annual Report. The document is relatively short (1971 characters) and serves as an earnings preview or earnings release rather than a full annual report. It provides key financial highlights and operational updates but does not contain full financial statements or detailed analysis. Therefore, it fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2024
2025-02-25 Chinese
君合律师事务所上海分所关于益方生物2022年限制性股票激励计划首次授予部分第二个归属期及预留授予部分（第二批）第一个归属期符合归属条件及部分限制性股票作废事项的法律意见书
Board/Management Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 restricted stock incentive plan of a company, detailing the approval, authorization, and conditions of stock grants and cancellations. It references specific board and shareholder meetings, regulatory compliance with Chinese securities laws, and stock incentive plan rules. The content focuses on management decisions and legal compliance related to stock incentive plans, including board and supervisory committee approvals and independent director opinions. It does not contain financial statements or audit results, nor is it a transcript or presentation. It is not an announcement of a report but a legal opinion document related to management and governance matters concerning stock incentives. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-01-17 Chinese
益方生物2024年年度业绩预亏公告
Regulatory Filings Classification · 95% confidence The document is titled as a '2024 Annual Performance Loss Forecast Announcement' for the company 益方生物科技（上海）股份有限公司. It provides preliminary financial estimates for the full fiscal year 2024, including expected net loss figures and comparisons to the prior year. The document explicitly states that the financial data are preliminary and unaudited, and that the final audited annual report will be published later. The document length is short (1217 characters) and it serves as an announcement of expected financial results rather than a full financial report. It does not contain detailed financial statements or comprehensive analysis. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of forecasted financial performance rather than the actual Annual Report (10-K) or Earnings Release (ER).
2025-01-17 Chinese
益方生物关于作废部分已授予尚未归属的限制性股票的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of certain granted but unvested restricted shares under a 2022 restricted stock incentive plan. It details board and supervisory meetings, approvals, legal opinions, and the impact of the cancellation on the company. The content focuses on corporate governance and equity incentive plan adjustments rather than financial results, earnings, or regulatory filings. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting results announcement. The document is a formal disclosure about management decisions related to stock incentives, which fits best under Board/Management Information (MANG) as it involves board resolutions and management decisions about equity incentives.
2025-01-17 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.